Risk factors of poor prognosis in patients with pyrrolidine alkaloid-induced hepatic sinusoidal obstruction syndrome after transjugular intrahepatic portosystemic shunt-Reference-Cited by-同舟云学术

Risk factors of poor prognosis in patients with pyrrolidine alkaloid-induced hepatic sinusoidal obstruction syndrome after transjugular intrahepatic portosystemic shunt

Published:2021-01-28 Issue:3 Volume:15 Page:720-729
ISSN:1936-0533
Container-title:Hepatology International
language:en
Short-container-title:Hepatol Int

Author:

Xiao Jiangqiang,Tu Jingjing,Zhang Han,Zhang Feng,Zhang Wei,Xu Hui,Yin Qin,Yang Jian,Han Hao,Wang Yi,Zhang Bin,Peng Chunyan,Zou Xiaoping,Zhang Ming,Zhuge Yuzheng^ORCID

Funder

National Natural Science Foundation of China

Publisher

Springer Science and Business Media LLC

Subject

Hepatology

Link

https://link.springer.com/content/pdf/10.1007/s12072-020-10126-x.pdf

Reference26 articles.

1. Chojkier M. Hepatic sinusoidal-obstruction syndrome: toxicity of pyrrolizidine alkaloids. J HEPATOL. 2003;39:437–46.

2. Zhuge YZ, Liu YL, Xie WF, et al. Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome. J Gastroen Hepatol. 2019;34:634–42.

3. Yang XQ, Ye J, Li X, et al. Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome–Pathogenesis, clinical manifestations, diagnosis, treatment, and outcomes. World J Gastroenterol. 2019;28:3753–63.